Jax DiEugenio

Jax DiEugenio joined MJH Life Sciences in 2024, first as an editorial intern before transitioning into a full-time assistant editor for OncLive. A recent College of New Jersey graduate, Jax majored in Journalism/ Professional Writing with minors in Public Health and Anthropology. He is also pursuing a Master's Degree in Public Health, concentrating on health communications.

Articles

ARANOTE Data Highlight Darolutamide Plus ADT as a Potential Chemo-Free Option in mHSPC

October 17th 2024

Fred Saad, MD, FRCS, discusses efficacy and safety data for darolutamide plus ADT in metastatic hormone-sensitive prostate cancer.

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

October 16th 2024

Drs Park and Patil delve into the evolving SCLC treatment paradigm by examining data from recent studies and focus on treatment developments for patients with ALK-positive NSCLC.

T-DXd Demonstrates Efficacy in HER2+ Metastatic Breast Cancer With Stable or Active Brain Metastases

October 16th 2024

Nancy U. Lin, MD, discusses findings from the DESTINY-Breast12 trial of trastuzumab deruxtecan in advanced HER2-positive breast cancer with brain metastases.

Accurate Diagnosis of dMMR/MSI-H Status Is Key for Nivolumab/Ipilimumab Treatment in mCRC

October 16th 2024

Thierry André, MD, discusses findings from subgroup analyses of the CheckMate 8HW trial of nivolumab/ipilimumab in dMMR/MSI-H metastatic colorectal cancer.

BTK Inhibitors vs Venetoclax: Considerations for Frontline Treatment Selection in CLL

October 14th 2024

Nitin Jain, MD, discusses the use of BTK inhibitor– and venetoclax-based regimens for the frontline treatment of chronic lymphocytic leukemia.

Response-Based Intermittent Ibrutinib Dosing Shows Safety, Feasibility in CLL

October 8th 2024

A phase 2 study of intermittent ibrutinib dosing shows reducing cardiovascular toxicity while maintaining efficacy in CLL.

Updated VISION Trial Data Showcase the Efficacy of Tepotinib in MET + NSCLC: With Martin Dietrich, MD

October 7th 2024

Martin Dietrich, MD, PhD, discusses updated efficacy findings from the 18-month follow-up of the phase 2 VISION trial.

NT-I7 After CAR T-Cell Therapy Enhances CAR T Factors in R/R DLBCL

October 7th 2024

NT-I7 with CAR T-cell therapy demonstrated an 81.1% objective response rate in relapsed DLBCL patients and a manageable safety profile.

Gotistobart Plus Pembrolizumab Shows Activity in Platinum-Resistant Ovarian Cancer

October 7th 2024

Gotistobart plus pembrolizumab demonstrated antitumor activity and a manageable safety profile in platinum-resistant ovarian cancer.

Park and Leyfman Hope to Advance Mission of MedNews Week Through Collaboration With OncLive

October 4th 2024

Chandler Park, MD, FACP, and Yan Leyfman, MD, discuss their partnership with OncLive and future goals for MedNews Week.

Long-Term Data Add to Prognostic Value of TILs in Treatment De-Escalation in Early HER2+ Breast Cancer

October 4th 2024

Maria Vittoria Dieci, MD, discusses the prognostic value of tumor-infiltrating lymphocytes in patients with early HER2-positive breast cancer.

Immunotherapy Advances Expand the SCLC Treatment Paradigm: With Chandler Park, MD, and Tejas Patil, MD

October 2nd 2024

Drs Park and Patil discuss the evolving small cell lung cancer treatment paradigm, focusing on PCI, immune checkpoint inhibitors, and recent study data.

Park and Leyfman Aim to Connect Oncology Community Through MedNews Week

October 2nd 2024

Chandler Park, MD, FACP, and Yan Leyfman, MD, discuss the goal of providing educational oncology content globally to oncologists via MedNews Week.

Mezigdomide Plus Tazemetostat and Dexamethasone Is Effective and Safe in Refractory Myeloma

September 30th 2024

Mezigdomide, tazemetostat, and dexamethasone demonstrated early efficacy signals in patients with refractory multiple myeloma.

Integration of Lutetium Lu 177 Vipivotide Tetraxetan Highlights Potential of Radioligands in Prostate Cancer

September 30th 2024

Daniel J. George, MD, discusses ongoing research with radioligand therapy in prostate cancer and its potential role in novel settings and combinations.

Belantamab Mafodotin Plus KRd Is Effective With Manageable Toxicities in R/R Multiple Myeloma

September 30th 2024

Belantamab mafodotin plus KRd was associated with a manageable safety profile and deep responses in pretreated patients with multiple myeloma.

Meta-Analysis Reveals Potential Role of Clonal Hematopoiesis on Allogeneic and Autologous HSCT Outcomes

September 27th 2024

Shyam A. Patel, MD, PhD, discusses findings from a meta-analysis of the effect of clonal hematopoiesis on outcomes for hematopoietic stem cell transplant.

No Significant PFS Association Is Seen Between Chemotherapy Backbone and HRD Status in First-Line TNBC

September 25th 2024

A statistically significant difference in PFS was not observed between chemotherapy backbone and HRD status in first-line TNBC.

BL-B01D1 Shows Preliminary Efficacy, Safety in Pretreated Advanced Urothelial Carcinoma

September 24th 2024

BL-B01D1 displayed safety and preliminary efficacy in previously treated locally advanced or metastatic urothelial carcinoma.

Tapotoclax Demonstrates Safety, Yields Anti-Leukemic Effects but No Responses in MDS Following HMAs

September 22nd 2024

Tapotoclax showed manageable safety, and it reduced bone marrow blasts and transfusion dependence in MDS after HMAs.